Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Phase 1

Conditions: Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)

Interventions: Biological: CD19 CAR engineered autologous T-cells
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna

First Posted Date: 2020-12-04

Last Posted Date: 2021-03-19

Lead Sponsor: Sabz Biomedicals

Target Recruit Count: 22

Registration Number: NCT04653493

Locations: 🇮🇷
Gene therapy research center, Shariati hospital, Tehran university of medical sciences, Iran, Tehran, Iran, Islamic Republic of
🇮🇷
Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

CAR-T Cells for HIV Infection

Phase 1

Recruiting

Conditions: HIV Infections

Interventions: Biological: LVgp120duoCAR-T cells, low dose
Drug: Cyclophosphamide
Biological: LVgp120duoCAR-T cells, high dose
Other: Analytic Treatment Interruption

First Posted Date: 2020-12-01

Last Posted Date: 2024-06-18

Lead Sponsor: Steven Deeks

Target Recruit Count: 18

Registration Number: NCT04648046

Locations: 🇺🇸
Zuckerberg San Francisco General, San Francisco, California, United States
🇺🇸
University of California, Davis, Sacramento, California, United States

NeoTIL in Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumor, Adult

Interventions: Biological: NeoTIL
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Radiation: Radiotherapy

First Posted Date: 2020-11-25

Last Posted Date: 2023-10-13

Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Target Recruit Count: 42

Registration Number: NCT04643574

Locations: 🇨🇭
centre hospitalier universitaire vaudois (CHUV), Lausanne, Vaud, Switzerland

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Phase 1

Recruiting

Conditions: Non Hodgkin Lymphoma
Lymphoma, Non-Hodgkin
Relapsed Non Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
B Cell Non-Hodgkin's Lymphoma
Lymphoma

Interventions: Genetic: CB-010
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2020-11-20

Last Posted Date: 2024-11-21

Lead Sponsor: Caribou Biosciences, Inc.

Target Recruit Count: 72

Registration Number: NCT04637763

Locations: 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 32 locations

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Triple-Negative Breast Carcinoma
Metastatic Urothelial Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions: Drug: Atezolizumab
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
Biological: PD1 Inhibitor

First Posted Date: 2020-11-20

Last Posted Date: 2023-08-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT04639245

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

Phase 3

Recruiting

Conditions: Hodgkin Lymphoma, Adult

Interventions: Drug: Doxorubicin
Drug: Bleomycin
Drug: Vinblastine
Drug: Cyclophosphamide
Drug: Dacarbazine
Drug: Etoposide
Drug: Vincristine
Drug: Dexamethasone

First Posted Date: 2020-11-20

Last Posted Date: 2022-11-01

Lead Sponsor: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

Target Recruit Count: 300

Registration Number: NCT04638790

Locations: 🇮🇳
Tata Memorial Hospital, Mumbai, OPD-81 Main building, Dr. E Borges Road, Parel 400012, India
🇷🇺
The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow, Russian Federation

FT819 in Subjects With B-cell Malignancies

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Lymphoma, B-Cell
Precursor B-Cell Acute Lymphoblastic Leukemia

Interventions: Drug: FT819
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: IL-2
Drug: Bendamustine

First Posted Date: 2020-11-16

Last Posted Date: 2024-08-02

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 54

Registration Number: NCT04629729

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 14 locations

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Early Phase 1

Conditions: Adult B Acute Lymphoblastic Leukemia

Interventions: Drug: CD19 CAR-T
Drug: CD22 CAR-T
Drug: CD19+CD22 CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Target Recruit Count: 50

Registration Number: NCT04626726

Locations: 🇨🇳
No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Phase 2

Recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Acalabrutinib
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Doxorubicin Hydrochloride
Drug: Prednisone
Biological: Rituximab
Biological: Rituximab and Hyaluronidase Human

First Posted Date: 2020-11-13

Last Posted Date: 2024-03-12

Lead Sponsor: Academic and Community Cancer Research United

Target Recruit Count: 45

Registration Number: NCT04626791

Locations: 🇺🇸
Ochsner NCI Community Oncology Research Program, New Orleans, Louisiana, United States
🇺🇸
Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States

and more 4 locations

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Early Phase 1

Conditions: Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: CD19 CAR-T
Drug: CD22 CAR-T
Drug: CD 19+22
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Target Recruit Count: 50

Registration Number: NCT04626765

Locations: 🇨🇳
No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy